Summary Cyclophosphamide (CP) administration to rats in a single i.p. dose (200mg kg1), while producing urinary bladder toxicity and 30-40% depression of the hepatic microsomal mixed function oxidase (MFO), failed to produce any depression of MFO activities in extrahepatic tissues such as lung, kidney and intestine. Phenobarbital pretreatment of the rats, which is known to enhance hepatic microsomal activation of CP, protected against CP-induced urinary bladder toxicity and the depression of hepatic MFO activities. This protection appears to be, at least in part, related to phenobarbital induction of hepatic cytochrome P-450 isozyme(s) that metabolizes CP to a new metabolite tentatively identified as didechlorodihydroxycyclophosphamide.
The microsomal mixed function oxidase system, principally found in the liver, is involved in the activation and detoxification of numerous xenobiotics including carcinogens, drugs and pesticides, and some endogenous bio-chemicals such as steroids and fatty acids. During recent years ample evidence has accumulated to demonstrate the existence in hepatic microsomes of multiple forms of cytochrome P-450, the terminal enzyme of the oxidase system (Guengerich, 1979; Guengerich et al., 1982) . This evidence has resulted from the application of gel electrophoresis, immunological, and recombinant DNA techniques in the investigation of cytochrome P-450 multiplicity in hepatic microsomes from several species of animals treated with different types of microsomal enzyme inducers (Guengerich, 1979; Guengerich et al., 1982; Fujii-Kuriyama et al., 1982; Mizukami et al., 1983) . Phenobarbital, a commonly used prototype inducer, has been shown to induce at least four different forms of cytochrome P-450 in rats with overlapping but different substrate specificities (Guengerich 1979; Guengerich et al., 1982) . Phenobarbital treatment has also been reported to induce cyclophosphamide metabolism in rodents and humans (Jao et al., 1972; Sladek, 1972; Bagley et al., 1973) .
Cyclophosphamide (CP), an oxazaphosphorine, is an important drug in the treatment of cancer and certain diseases of immunological aetiology (Friedman et al., 1979) . It has also found application in the immunosuppressive preparation Correspondence: H.L. Gurtoo. Received 10 May 1984; and in revised form 9 October 1984. of patients for organ and tissue transplantation (Santos et al., 1976; Zinke & Woods, 1977; Friedman et al., 1979) .
CP is inactive per se and requires microsomal mixed function oxidase-mediated metabolism to activated metabolites capable of binding covalently to nucleic acids and proteins. The commonly accepted scheme of CP metabolism involves intermediate formation of 4-hydroxy-CP which undergoes ring-opening to form aldophosphamide, an isomer of 4-hydroxy-CP (Figure 1 ). Both 4-hydroxy-CP and aldophosphamide, can be detoxified by cytosolic oxidases/reductases (Cox et al., 1975; Hipkens et al., 1981) . Alternatively, aldophosphamide can undergo non-enzymatic ,B elimination to release acrolein and phosphoramide mustard. Acrolein is believed to be responsible for CP-induced haematuria, one of the limiting toxicities of CP, and phosphoramide mustard has been assigned the distinction of being the therapeutically active metabolite of CP and is believed to be responsible for both the antitumour activity and immunosuppression (Friedman et al., 1979; Brock et al., 1979; Cox, 1979; Berrigan et al., 1982) .
During the recent years we have reported that, in addition to being responsible for haematuria, acrolein may also denature cytochrome P-450; both effects are believed to result from the reaction of the double bond in acrolein with free sulfhydryl groups in proteins MFO, mixed function oxidase; CP, cyclophosphamide; 4-OHCP, 4-hydroxycyclophosphamide; 4-ketoCP, 4-ketocyclophosphamide; Aldo-P, aldophosphamide; carboxy P, carboxyphosphamide.
one would anticipate some degree of relationship between this induction and the chemotherapeutic and toxic effects of CP. We have investigated this relationship in the rat in the context of the effects of CP on mixed function oxidase in liver and extrahepatic tissue and of the ability of CP to induce haematuria. These investigations have led to suggestions of the participation of novel detoxification pathways of CP metabolism catalyzed by hepatic microsomes from phenobarbital treated rats.
Materials and methods
Sources of CP and other chemicals needed for enzyme assays have been detailed earlier (Hipkens et al., 1981; Gurtoo et al., 1981; Berrigan et al., 1982) .
Animals tissue and enzyme preparation Male rats (175-225 g) were used in all the studies. Source and housing details are given elsewhere (Berrigan et al., 1982) . CP was injected i.p. as a single injection at a dose of 200mg kg-1, and the rats were killed 4 days later. Microsomes or 15,000g supernatant from liver, kidney, lung and intestine were isolated as described previously (Gurtoo & Parker, 1977; Gurtoo et al., 1981; Berrigan et al., 1982; Porter et al., 1982) , and the protein content was determined by the method of Lowry et al. (1951) , using bovine serum albumin as the reference standard. Urinary bladders, when needed, were removed, immersed in 10% buffered formalin and stored for histopathology conducted at a later date.
Enzyme assays Cytochrome P-450 was determined according to the method of Omura & Sato (1964) using an Aminco DW-2 spectrophotometer. The calculation of cytochrome P-450 content is based on the extinction coefficient of 91 mM 1 cm -1. Aryl hydrocarbon hydroxylase (AHH) and aminopyrine demethylase activities were determined by previously described methods Berrigan et al., 1982) .
Histopathology
Urinary bladders were fixed in Bouin's solution and sectioned at 5 gm and the sections for microscopic examination were stained with haematoxylin and eosin (Berrigan et al., 1982) .
Purification of cytochrome P-450 Cytochrome P-450 was purified from the hepatic microsomes of phenobarbital pretreated male rats by the method of Guengerich & Martin (1980) . Sodium phenobarbital was included in the drinking water as a 0.1% solution for 7 days prior to the sacrifice of the animals. The detergent solubilized hepatic microsomes were subjected to chromatography on octylamino-Sepharose-4B. The cytochrome P-450 band eluted from this column was subjected to DEAE-cellulose chromatography as described by Guengerich & Martin (1980 (Berrigan et al., 1982) . At the termination of the incubation, the mixture was extracted twice with 3 to 4 volumes of chloroform: isoamyl alcohol (95:5) and an aliquot was counted for the quantitation of the polar metabolite formation.
Metabolism by the purified Cytochrome P-450 (Table I) . While CP caused a depression of AHH by 37% and aminopyrine demethylase by 30% in the liver, it failed to produce any inhibition of these activities in lungs, kidneys and intestine. Instead, CP was found to increase intestinal AHH activity by about 50%.
Effects ofphenobarbital on CP-induced depression of mixedfunction oxidase in liver and extrahepatic tissues Phenobarbital pretreatment of rats has been reported to induce CP metabolism (Sladek, 1972; Gurtoo et al., 1978) . Because of these reports and In accordance with several other reports (Conney, 1967) , phenobarbital was found to enhance the microsomal mixed function oxidase activities; it increased aminopyrine demethylase activity by 61% and AHH activity by 42%. In contrast and as expected from previous studies Berrigan et al., 1982) , CP decreased these mixed function oxidase-mediated activities by 30 and 37%, respectively. However, when CP was combined with phenobarbital pretreatment, phenobarbital failed to produce an enhancement in the depression of these activities; but, on the other hand, the activities of the CP plus phenobarbital group were 37% and 20%, respectively, higher than the control group. Even if the activities of the CP plus phenobarbital group are compared with phenobarbital treatment alone, the presence of phenobarbital decreased the activities half as much as CP treatment alone decreased these activities in the control animals (aminopyrine demethylase, 15% vs 30%; AHH, 17% vs 37%). These results suggest that phenobarbital probably induces various forms of cytochrome P-450 isozymes that participate in the activation as well as in the detoxification of CP.
Phenobarbital pretreatment also failed to render CP depressant to the mixed function oxidase activities in extrahepatic tissues such as kidney, lungs and intestine.
Effect ofphenobarbital on the urotoxicity of CP As reported previously (Berrigan et al., 1982) CP treatment produced acute histopathologic changes in the urinary bladders of rats examined 4 days after CP administration. These changes included thickening of the bladder mucosa, ulceration, and haemorrhagic and necrotic lesions in the mucosa. Bloody exudate containing cellular debris, fibrin and inflammatory cells was seen in the lumen. In addition, focal changes of the seemingly intact mucosa, including thinning, atypia and Karyorrhexis were also observed. Diffuse oedematous and haemorrhagic changes were also seen in the submucosa.
Pretreatment of the rats with phenobarbital alone or treatment of the rats with saline (control) had no demonstrable effect on the urinary bladder histology. However, when CP was administered to rats pretreated with phenobarbital, only one of four rats showed slight atypia and vacuolization of epithelial cells of the mucosa and slight oedematous and haemorrhagic changes in the submucosa. These changes were mild relative to CP treatment alone. These results clearly demonstrate the ability of phenobarbital to afford significant protection against CP-induced bladder damage.
Metabolism of CP by hepatic microsomes
The effects of phenobarbital and 3-methylcholanthrene pretreatment on the formation of the polar metabolites of CP by the hepatic microsomes are shown in Table III [14C]-labelled metabolites were recovered in the aqueous phase following chloroform extraction of the incubation mixture. While 3-methylcholanthrene pretreatment of the rats resulted in a mild depression of the metabolism, phenobarbital pretreatment enhanced the polar metabolite formation 10 to 14-fold. Thin layer chromatographic and HPLC analyses of the polar fractions derived from larger incubations repeatedly revealed the presence of a polar metabolite, which has been tentatively identified as didechlorodihydroxy-CP (described below). This was not formed in incubations lacking in NADPH and was produced in only negligible amounts by hepatic microsomes from control rats, whereas hepatic microsomes from phenobarbital treated rats produced large quantities of this metabolite.
The data on phenobarbital ( Table III) Metabolism of CP by the purified cytochrome P-450 from phenobarbital-treated rats Cytochrome P-450, purified from phenobarbital treated rats, was employed in the reconstituted system to investigate the metabolism of both [chloroethyl-3H]-CP and [4-14C]-CP. As described earlier, the incubations were extracted with chloroform, the aqueous phase was lyophilized, and the residue extracted sequentially with chloroform and methanol.
Radioactivity measurements demonstrated that chloroform extracts consistently contained 20-35% Methanol extracts, after treatment with diazomethane to stabilize phosphoramide mustard as its methyl ester, revealed on thin layer chromatography (chloroform:methanol, 9:1) only trace amounts of phosphoramide mustard, while the major amount of radiactivity remained at the origin of the silica gel plates. The high polarity of the major radioactivite band was established by TLC in different solvent systems.
Side 10] demonstrated by radioscanning that the Rfs of the major radioactive component in extracts of both labels were identical. Diazomethane treatment of both the [3H] and [14C]-labelled major metabolite, either in total methanol extracts or after TLC isolation, had no effect on TLC mobility; this property demonstrates the absence of an acidic function in the metabolite and indicates that the metabolite has retained the oxazaphosphorine ring intact.
Consideration of the foregoing data led to the tentative identification of the metabolite as didechlorodihydroxy-CP. Such a structure would be expected to be polar and to be unaffected by diazomethane and would retain both [3H] and [14C] labels.
Likely routes to didechlorodihydroxy-CP would involve selective hydrolytic displacement of the chlorine groups in CP without concomitant hydrolysis of phosphoramide or P(V) alkyl ester bonds. Since phosphoramides are sensitive to acid hydrolysis but resist base hydrolysis, synthesis was attempted by selective chlorine displacement from [chloroethyl-3H]-CP by hydroxide ion in dilute potassium hydroxide. The method was successful, and the tritiated dihydroxy analog of CP was isolated by TLC. Structural confirmation was obtained by mass spectral analysis using the fast atom bombardment technique. In the normal (positive) mode, an intense peak of m/z 225 (strongest peak in spectrum) was observed ([M + 1]+). In the negative mode, a peak of m/z 223 (strongest peak in spectrum) was observed ([M-1i) .
Synthetic 2-[bis(2-hydroxyethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide (didechlorodihydroxy-CP) was compared by TLC with the major metabolite generated in incubates of the isolated cytochrome P-450 fraction with [chloroethyl-3H]-CP and [4-14C]-CP. Identical Rfs were obtained in different solvent systems upon side-by-side TLC on silica gel (Table IV) . . Our studies have incriminated cyclophosphamide metabolite acrolein in the depression of liver cytochrome P-450 and, in agreement with other reports (Brock et al., 1979; Cox, 1979) , have also implicated acrolein in the causation of CP-associated haematuria and bladder toxicity (Berrigan et al., 1982 (Guengerich et al., 1982) and associated activities, including the metabolism of CP (Sladek, 1972; Gurtoo et al., 1978) . Sladek (1972) reported that phenobarbital pretreatment enhanced the hepatic microsomal metabolism of CP to its alkylating metabolites; it decreased the Km and enhanced the Vmax by about 7-fold. However, various attempts to enhance the chemotherapeutic activity and whole body toxicity of CP have produced conflicting results. Sladek (1972) reported that phenobarbital pretreatment of male rats did not alter the therapeutic activity of CP against Walker 256 carcinosarcoma. In other studies involving mice, Field et al. (1971) found that while phenobarbital pretreatment accelerated the production of alkylating metabolites of CP, duration of antileukaemic activity against L1210 leukaemic cells was shortened by phenobarbital. Alberts & Wetters (1976) found a constant 90% (1-log) reduction in the toxicity of CP to P388 leukaemic colony forming units in mice. In various studies on the pharmacokinetics of CP in patients, phenobarbital was found to accelarate the metabolism of CP and reduce its half-life (Mallett et al., 1969; Jao et al., 1972; Bagley et al., 1973) . One report even suggested that this increased activation in humans may offer therapeutic advantage in the treatment of cancer (Mallett et al., 1969) . However, Jao et al. (1972) found that phenobarbital, while increasing the rate of biotransformation of CP 2 to 3-fold, had no quantitatively significant effect on the distribution and renal excretion of CP. These investigators concluded that phenobarbital should marginally enhance the efficacy and toxicity of CP in man.
In the present report, we have demonstrated that phenobarbital, which was earlier found to enhance the formation of protein-and DNA-binding metabolites of CP formed in vitro by the hepatic microsomes (Gurtoo et al., 1978) , failed to enhance CP-induced depression of the hepatic mixed function oxidase and also protected against the toxicity of CP to the urinary bladder. This enigmatous observation led to the rationalization that phenobarbital, which is known to induce various forms of cytochrome P-450, was inducing both the activation and the detoxification of CP. If this was true, it would explain the reported effects of phenobarbital pretreatment on the therapeutic efficacy and toxicity of CP: increase in the formation of alkylating metabolites of CP both in vivo and in vitro; decrease in t-, of CP, and minimal effect on the toxicity and therapeutic activity of CP.
In fulfilment of the requirement to demonstrate enhancement in the detoxification of CP by phenobarbital, we demonstrated the formation of a very polar metabolite, tentatively identified as didechlorodihydroxy-CP. This metabolite was found to be one of the major metabolites of CP catalyzed by cytochrome P-450 isolated from phenobarbital treated rats. This biotransformation would essentially yield a detoxified product of CP. We do not know at this stage whether the monodechlorinated metabolite exists or whether 4-hydroxy CP could be further metabolized to form didechlorinated products. Further metabolism of the primary metabolites by the mixed function oxidase system is a well established metabolic route in the biotransformation of several polycyclic aromatic hydrocarbons (Gelboin, 1980) .
A precedent for replacement of chlorine by the hydroxyl group in CP by cytochrome P-450 can be found in studies on mixed function oxidation of 1,2-dichloroethane to 2-chloroethanol by . Additionally, in studies on the urinary metabolites of CP in sheep, Bakke et al. (1972) identified a minor metabolite whose structure is similar to that of the cytochrome P-450 metabolite. Mass spectral analysis led to the suggestion that the sheep metabolite was 5-or 6-keto-didechlorodihydroxy-CP. The sheep metabolite establishes a precedent for replacement of chlorine by the hydroxyl group in CP in vivo.
The existence of a phenobarbital-inducible cytochrome P-450 isozyme that is capable of dechlorinating CP is consistent with the inability of phenobarbital to appreciably enhance the experimental antitumour effects of CP.
In summary, in this report, we have developed mechanistic information at the biochemical level to explain why phenobarbital may not enhance the efficacy of CP and also that phenobarbital may be useful in blocking some of the deleterious effects of CP, especially denaturation of cytochrome P-450 and bladder toxicity.
